Regression of metastatic carcinoid tumors with octreotide therapy: Two case reports and a review of the literature

Journal of Surgical Oncology

Volumn 79, Issue 3, 2002, Pages 180-187

  Leong, Wey L ^a   Pasieka, Janice L ^a,b  

^a UNIVERSITY OF CALGARY   (Canada)

^b CALGARY HEALTH REGION   (Canada)

Author keywords

Metastatic carcinoid tumors; Octreotide

Indexed keywords

OCTREOTIDE;

ADOLESCENT; ADULT; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER PALLIATIVE THERAPY; CANCER REGRESSION; CARCINOID; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; HUMAN; HUMAN TISSUE; LIVER METASTASIS; LYMPH NODE METASTASIS; MALE; METASTASIS; NEUROENDOCRINE TUMOR; PORTAL PHLEBOGRAPHY; PRIORITY JOURNAL; PROGNOSIS; TUMOR REGRESSION;

ADOLESCENT; ANTINEOPLASTIC AGENTS, HORMONAL; APPENDICEAL NEOPLASMS; CARCINOID TUMOR; FEMALE; HUMANS; JEJUNAL NEOPLASMS; LIVER NEOPLASMS; MALE; MIDDLE AGED; OCTREOTIDE; REMISSION INDUCTION;

EID: 0036196384     PISSN: 00224790     EISSN: None     Source Type: Journal    
DOI: 10.1002/jso.10062     Document Type: Article

References (36)

1. Carcinoid tumors
2. Octreotide
3. Carcinoid tumor regression with high-dose octreotide acetate. A patient report
4. The somatostatin analogue octreotide inhibits neuroblastoma growth in vivo
5. Tamoxifen and somatostatin affect tumors by inducing apoptosis
6. Partial inhibition of the growth of transplanted Dunning rat prostate tumors with the long-acting somatostatin analogue sandostatin (SMS 201-995)
7. In vitro and in vivo inhibition of human small cell carcinoma (NCI-H69) growth by a somatostatin analogue
8. Inhibition of growth of two human pancreatic adenocarcinomas in vivo by somatostatin analog SMS 201-995
9. Response of human lung xenografts to treatment with a somatostatin analogue (Somatuline)
10. Antiproliferative effects of the somatostatin analogue octreotide (SMS 201-995) on ZR75-1 human breast cancer cell in vivo and in vitro
11. Inhibitory and stimulatory effects of somatostatin on two human pancreatic cancer cell lines: A primary role of tyrosine phosphatase SHP-1
12. Systemic therapy for metastatic or residual extrapancreatic neuroendocrine tumours
13. Octreotide as an antineoplastic agent in the treatment of functional and nonfunctional neuroendocrine tumors
14. Case report. Efficacy of octreotide in the regression of a metastatic carcinoid tumour despite negative imaging with In-111-pentetreotide (octreoscan)
15. Regression of metastatic carcinoid tumor after valvular surgery for carcinoid heart disease
16. Tumour regression of an ileal carcinoid under the treatment with the somatostatin analogue SMS 201-995
17. Metatasizing carcinoma of the breast with neuroendocrine differentiation: Combined treatment with tamoxifen and octreotide
18. Treatment of the malignant carcinoid syndrome: Evaluation of a long-acting somatostatin analogue
19. Clinical efficacy of octreotide in the treatment of metastatic neuroendocrine tumors. A study by the Italian trials in medical oncology group
20. Gastroenteropancreatic endocrine tumours: Effect of sandostatin on tumour growth
21. Long-term management of the carcinoid syndrome: Treatment with octreotide alone and in combination with alpha-interferon
22. Treatment of metastatic carcinoid tumors using multimodality therapy of octreotide acetate, intra-arterial chemotherapy, and hepatic arterial chemoembolization
23. Use of somatostatin analogue in management of carcinoid syndrome
24. Somatostatin analog Phase I trials in neuroendocrine neoplasms
25. Complete histological regression of metastatic carcinoid tumour after treatment with octreotide
26. Long-term treatment of acromegaly with somatostatin analogue SMS 201-995
27. The role of somatostatin in the regulation of anterior pituitary hormone secretion and the use of its analogs in the treatment of human pituitary tumors
28. Octreotide treatment of acromegaly: A randomized, multicenter study
29. Octreotide acetate long-acting fomulation versus open-labelled subcutaneous octreotide acetate in malignant carcinoid syndrome
30. Urinary serotonin in the diagnosis of carcinoid tumors
31. Chromogranin A as a serum marker for neuroendocrine neoplasia. Comparison with neuro-specific enolase and the alpha subunit of glycoprotein hormones
32. [111In-DTPA-D-Phe1]octreotide scintigraphy in patients with carcinoid tumours: The predictive value for somatostatin analogue treatment
33. Stimulation of tyrosine phosphatase and inhibition of cell proliferation by somatostatin analogues: Mediation by human receptor subtypes SSTR1 and SSTR2
34. Inhibition of cell proliferation by the somatostatin analogues RC-160 is mediated by somatostatin receptor subtypes SSTR2 and SSTR5 through different mechanisms
35. Expression of somatostatin receptors in peritumoral veins of human tumors